Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) has issued an announcement.
ResMed Inc. has filed a notice for the proposed sale of securities under Rule 144, indicating that Brett Sandercock, an officer of the company, plans to sell 3,000 shares of common stock. The aggregate market value of these shares is approximately $742,620, with the sale expected to occur on November 3, 2025. This transaction follows a previous sale of 3,000 shares by Sandercock in September 2025, which yielded gross proceeds of $812,310. The announcement reflects ongoing insider trading activities and may impact stakeholder perceptions regarding the company’s stock performance.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$47.04 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc. operates in the healthcare industry, focusing on the development and manufacturing of products for the treatment of sleep disorders and respiratory care. The company is known for its innovative solutions in sleep apnea treatment and related respiratory conditions, serving a global market with a strong emphasis on improving patient outcomes and quality of life.
Average Trading Volume: 1,136,324
Technical Sentiment Signal: Buy
Current Market Cap: A$55.08B
Find detailed analytics on RMD stock on TipRanks’ Stock Analysis page.